|
1) 吉川徳茂, 本田雅敬, 関根孝司, 他. 日本小児腎臓病学会学術委員会小委員会｢小児ネフローゼ症候群薬物治療ガイドライン作成委員会｣. 小児特発性ネフローゼ症候群薬物治療ガイドライン1. 0版. 日本小児科学会雑誌. 2005; 109: 1066-75
|
|
|
|
2) Ishikura K, Ikeda M, Hattori S, et al. Effective and safe treatment with cyclosporine in nephro-tic children: a prospective, randomized multicenter trial. Kidney Int. 2008; 73: 1167-73
|
|
|
|
|
3) Hamasaki Y, Yoshikawa N, Hattori S, et al. Cyclosporine and steroid therapy in children with steroid-resistant nephritic syndrome. Pediatr Nephrol. 2009; 24: 2177-85
|
|
|
|
|
|
4) Inoue Y, Iijima K, Nakamura H, et al. Two-year cyclosporin treatment in children with steroid-dependent nephrotic syndrome. Pediatr Nephrol. 1999; 13: 33-8
|
|
|
|
|
|
5) Iijima K, Hamahira K, Tanaka R, et al. Risk factors for cyclosporine-induced tubulointerstitial lesions in children with minimal change nephro-tic syndrome. Kidney Int. 2002; 61: 1801-5
|
|
|
|
|
|
6) Latta K, von Schnakenburg C, Ehrich JH. A meta-analysis of cytotoxic treatment for frequently relapsing nephrotic syndrome in children. Pediatr Nephrol. 2001; 16: 271-82
|
|
|
|
|
|
7) Anolik J, Sanz I, Looney J. B cell depletion therapy in systemic lupus erythematosus. Current Rheumatology Reports. 2003; 5: 350-6
|
|
|
|
|
|
8) Looney RJ. Treating human autoimmune disease by depletion B cells. Ann Rheum Dis. 2002; 61: 863-6
|
|
|
|
|
|
9) Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994; 83: 435-45
|
|
|
|
|
|
10) Clynes RA, Towers TL, Presta LG, et al. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med. 2000; 6: 443-6
|
|
|
|
|
|
11) Golay J, Zaffaroni L, Vaccari T, et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood. 2000; 95: 3900-8
|
|
|
|
|
|
12) Taji H, Kagami Y, Okada Y, et al. Growth inhibition of CD20-positive B lymphoma cell lines by IDEC-C2B8 anti-CD20 monoclonal antibody. Jpn J Cancer Res. 1998; 89: 748-56
|
|
|
|
|
|
13) Shan D, Ledbetter JA, Press OW. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood. 1998; 91: 1644-52
|
|
|
|
|
|
14) Benz K, Dotsch J, Rascher W, et al. Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy. Pediatr Nephrol. 2004; 19: 794-7
|
|
|
|
|
|
15) Nozu K, Iijima K, Fujisawa M, et al. Rituximab treatment for posttransplant lymphoproliferative disorder (PTLD) induces complete remission of recurrent nephrotic syndrome. Pediatr Nephrol. 2005; 20: 1660-3
|
|
|
|
|
|
16) Bagga A, Sinha A, Moudgil A. Rituximab in Patients with the steroid-resistant nephrotic syndrome. N Engl J Med. 2007; 356: 2751-2
|
|
|
|
|
|
17) Nakayama M, Kamei K, Nozu K, et al. Rituximab for refractory focal segmental glomerulosclerosis. Pediatr Nephrol. 2008; 23: 481-5
|
|
|
|
|
|
18) Gilbert RD, Hulse E, Rigden S. Rituximab therapy for steroid-dependent minimal change nephrotic syndrome. Pediatr Nephrol. 2006; 21: 1698-700
|
|
|
|
|
|
19) Dötsch J, Müller-Wiefel DE, Kemper MJ. Rituximab: is replacement of cyclophosphamide and calcineurin inhibitors in steroid-dependent nephrotic syndrome possible？Pediatr Nephrol. 2008; 23: 3-7
|
|
|
|
|
|
20) Francois H, Daugas E, Bensman A, et al. Unexpected efficacy of rituximab in multirelapsing minimal change nephrotic syndrome in the adult: First case report and pathophysiological considerations. Am J Kidney Dis. 2007; 9: 158-61
|
|
|
|
|
|
21) Guigonis V, Dallocchio A, Baudouin V, et al. Rituximab treatment for severe steroid- or cyclosporine-dependent nephritic syndrome: a multicentric series of 22 cases. Pediatr Nephrol. 2008; 23: 1269-79
|
|
|
|
|
|
22) Smith GC. Is there a role for rituximab in the treatment of idiopathic childhood nephrotic syndrome？ Pediatr Nephrol. 2007; 22: 893-8
|
|
|
|
|
|
23) Hofstra JM, Deegens JK, Wetzels JF. Rituximab: effective treatment for severe steroid-dependent minimal change nephrotic syndrome？ Nephrol Dial Transplant. 2007; 22: 2100-2
|
|
|
|
|
|
24) Kamei K, Ito S, Nozu K, et al. Single dose of rituximab for refractory steroid-dependent nephritic syndrome in children. Pediatr Nephrol. 2009; 24: 1321-8
|
|
|
|
|
|
25) Sellier-Leclerc AL, Macher MA, et al. Rituximab efficiency in children with steroid-dependent nephrotic syndrome. Pediatr Nephrol. 2010; 25: 1109-15
|
|
|
|
|
|
26) Fujinaga S, Hirano D, Nishizaki N, et al. Single infusion of rituximab for persistent steroid-dependent minimal-change nephrotic syndrome after long-term cyclosporine. Pediatr Nephrol. 2010; 25: 539-944
|
|
|
|
|
|
27) Prytuła A, Iijima K, Kamei K, et al. Rituximab in refractory nephrotic syndrome. Pediatr Nephrol. 2010; 25: 461-8
|
|
|
|
|
|
28) Haffner D, Fischer DC. Nephrotic syndrome and rituximab: facts and perspectives. Pediatr Nephrol. 2009; 24: 1433-8
|
|
|
|
|
|
29) Kaito H, Kamei K, Kikuchi E, et al. Successful treatment of collapsing focal segmental glomerulosclerosis with a combination of rituximab, steroids and ciclosporin. Pediatr Nephrol. 2010; 25: 957-9
|
|
|
|
|
|
30) FDA Alert [12/2006]: Information for Healthcare Professionals: Rituximab (marketed as Rituxan) http: //www. fda. gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm126519. htm
|
|
|
|
|
|
31) Gea-Banacloche JC. Rituximab-associated infections. Semin Hematol. 2010; 47: 187-98
|
|
|
|
|
|
32) Chaumais MC, Garnier A, Chalard F, et al. Fatal pulmonary fibrosis after rituximab administration. Pediatr Nephrol. 2009; 24: 1753-5
|
|
|
|
|
|
33) Leon RJ, Gonsalvo A, Salas R, Hidalgo NC. Rituximab-induced acute pulmonary fibrosis. Mayo Clin Proc. 2004; 79: 949, 953
|
|
|
|
|
|
34) Kamei K, Ito S, Iijima K. Severe respiratory adverse events associated with rituximab infusion. Pediatr Nephrol. 2010; 25: 1193
|
|
|
|
|